Aspire Biopharma Holdings (ASBP) Change in Accured Expenses (2022 - 2026)

Aspire Biopharma Holdings (ASBP) has reported Change in Accured Expenses for 5 consecutive years, with $272474.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Change in Accured Expenses changed N/A year-over-year to $272474.0 in Q2 2026; TTM through Jun 2026 was $1.1 million, a 1104.39% increase from a year earlier, with the FY2025 full-year figure at $1.0 million, up 19.18% from the prior year.
• Change in Accured Expenses was $272474.0 for Q2 2026 at Aspire Biopharma Holdings, up from -$316955.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $781667.0 in Q4 2025 and troughed at -$316955.0 in Q1 2026.
• A 5-year average of $73310.7 and a median of $23098.0 in 2023 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses plunged 257.73% in 2023 and jumped 822.18% in 2024, its largest moves.
• Over 5 years, Change in Accured Expenses stood at $84618.0 in 2022, then plunged by 43.72% to $47626.0 in 2023, then plunged by 546.93% to -$212855.0 in 2024, then surged by 467.23% to $781667.0 in 2025, then sank by 65.14% to $272474.0 in 2026.
• The last three Change in Accured Expenses figures came in at $272474.0 (Q2 2026), -$316955.0 (Q1 2026), and $781667.0 (Q4 2025), per Business Quant data.